Literature DB >> 17845976

[Gemcitabine: from preclinic to clinic passing by pharmacokinetics].

François Lokiec1, Amélie Lansiaux.   

Abstract

Gemcitabine or Gemzar forms part of the class of the anti-cancer drugs antimetabolites. Gemcitabine is a structural analogue of the deoxycytidine with 2 fluorine atoms. There is a strong analogy between gemcitabine and cytosine arabinoside (Aracytine or Depocyt), at the same time structural, mechanistic and metabolic. However, if the intracellular derivatives triphosphate of gemcitabine seem more stable than those of the cytarabine, the two molecules move away from share their therapeutic activity. Indeed, if the cytosine arabinoside finds its place in the treatment of hematologic diseases, myeloblastic or lymphoblastic acute leukaemia and in acute myeloid leukaemias and myelodysplasy, gemcitabine sees its indications in the treatment of solid tumours such as non small cell lung cancer, adenocarcinoma of the pancreas, cancer of the bladder and metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845976

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.

Authors:  L Marconato; R Finotello; U Bonfanti; M Dacasto; L Beatrice; S Pizzoni; V F Leone; G Balestra; T Furlanello; C Rohrer Bley; L Aresu
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

2.  Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.

Authors:  Liang Li; Brooke L Fridley; Krishna Kalari; Gregory Jenkins; Anthony Batzler; Richard M Weinshilboum; Liewei Wang
Journal:  PLoS One       Date:  2009-11-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.